RU2000124084A - Chimeric antibody that binds to human CD40 (variants), nucleic acid molecule (variants), expression vector (variants), humanized antibody (variants), pharmaceutical composition for treating a T-cell mediated disease (variants), method for treating a patient for a disease mediated by T cells (options) - Google Patents

Chimeric antibody that binds to human CD40 (variants), nucleic acid molecule (variants), expression vector (variants), humanized antibody (variants), pharmaceutical composition for treating a T-cell mediated disease (variants), method for treating a patient for a disease mediated by T cells (options)

Info

Publication number
RU2000124084A
RU2000124084A RU2000124084/13A RU2000124084A RU2000124084A RU 2000124084 A RU2000124084 A RU 2000124084A RU 2000124084/13 A RU2000124084/13 A RU 2000124084/13A RU 2000124084 A RU2000124084 A RU 2000124084A RU 2000124084 A RU2000124084 A RU 2000124084A
Authority
RU
Russia
Prior art keywords
variable region
variants
seq
heavy chain
sequence
Prior art date
Application number
RU2000124084/13A
Other languages
Russian (ru)
Other versions
RU2220980C2 (en
Inventor
Алехандро А. АРАФФО
Диан ХОЛЛЕНБОГ
Энтони В. СИАДЭК
Карен К. БЕРРИ
Линда Дж. ХАРРИС
Барбара А. ТОРН
Юрген БАЖОРАТ
Уильям Д. ХЬЮЗ
Херрен ВУ
Джефри Д. УОТКИНС
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/026,291 external-priority patent/US6051228A/en
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of RU2000124084A publication Critical patent/RU2000124084A/en
Application granted granted Critical
Publication of RU2220980C2 publication Critical patent/RU2220980C2/en

Links

Claims (30)

1. Вариабельный участок легкой цепи, содержащий полную аминокислотную последовательность SEQ ID NO:l (Фиг. 4а), или его биологически активный фрагмент.1. The variable region of the light chain containing the complete amino acid sequence of SEQ ID NO: l (Fig. 4A), or a biologically active fragment thereof. 2. Вариабельный участок тяжелой цепи, содержащий полную аминокислотную последовательность SEQ ID NO:2 (Фиг. 4b), или его биологически активный фрагмент.2. The variable region of the heavy chain containing the complete amino acid sequence of SEQ ID NO: 2 (Fig. 4b), or a biologically active fragment thereof. 3. Химерное антитело, которое связывается с CD40 человека, содержащее легкую и тяжелую цепь, причем указанная легкая цепь содержит вариабельный участок по п. 1.3. A chimeric antibody that binds to human CD40 containing a light and heavy chain, said light chain comprising a variable region according to claim 1. 4. Химерное антитело, которое связывается с CD40 человека, содержащее легкую и тяжелую цепь, причем указанная тяжелая цепь содержит вариабельный участок по п. 2.4. A chimeric antibody that binds to human CD40 containing a light and a heavy chain, said heavy chain comprising a variable region according to claim 2. 5. Химерное антитело по п. 3, отличающееся тем, что указанная тяжелая цепь содержит вариабельный участок по п. 2.5. Chimeric antibody according to claim 3, characterized in that said heavy chain contains a variable region according to claim 2. 6. Химерное антитело, которое связывается с CD40 человека, содержащее легкую и тяжелую цепь, причем указанная легкая цепь содержит полную аминокислотную последовательность SEQ ID NO:4 или ее биологически активный фрагмент, а указанная тяжелая цепь содержит полную аминокислотную последовательность SEQ ID NO:3 или ее биологически активный фрагмент.6. A chimeric antibody that binds to human CD40 containing a light and heavy chain, said light chain containing the complete amino acid sequence of SEQ ID NO: 4 or a biologically active fragment thereof, and said heavy chain containing the complete amino acid sequence of SEQ ID NO: 3 or its biologically active fragment. 7. Молекула нуклеиновой кислоты, представляющая собой нуклеотидную последовательность, кодирующую вариабельный участок легкой цепи по п. 1.7. A nucleic acid molecule, which is a nucleotide sequence encoding a variable region of the light chain according to claim 1. 8. Молекула нуклеиновой кислоты, представляющая собой нуклеотидную последовательность, кодирующую вариабельный участок тяжелой цепи по п. 2.8. The nucleic acid molecule, which is a nucleotide sequence encoding the variable region of the heavy chain according to claim 2. 9. Вектор экспрессии, содержащий последовательность нуклеиновой кислоты по п. 7.9. An expression vector containing the nucleic acid sequence of claim 7. 10. Вектор экспрессии, содержащий последовательность нуклеиновой кислоты по п. 8.10. An expression vector containing the nucleic acid sequence of claim 8. 11. Гуманизированное антитело, содержащее фрагмент вариабельного участка легкой цепи по п. 1.11. Humanitariannet antibody containing a fragment of the variable region of the light chain according to claim 1. 12. Гуманизированное антитело, содержащее фрагмент вариабельного участка тяжелой цепи по п. 2.12. Humanitariannet antibody containing a fragment of the variable region of the heavy chain according to claim 2. 13. Фармацевтическая композиция, содержащая химерное антитело по п. 5.13. A pharmaceutical composition comprising a chimeric antibody according to claim 5. 14. Фармацевтическая композиция, содержащая химерное антитело по п. 6.14. A pharmaceutical composition comprising a chimeric antibody according to claim 6. 15. Химерное антитело, которое связывается с CD40 человека, содержащее вариабельный участок легкой цепи и вариабельный участок тяжелой цепи, причем указанный вариабельный участок легкой цепи имеет аминокислотную последовательность, по крайней мере, на 90% идентичную последовательности вариабельного участка легкой цепи по п. 1.15. A chimeric antibody that binds to human CD40 comprising a light chain variable region and a heavy chain variable region, wherein said light chain variable region has an amino acid sequence that is at least 90% identical to the sequence of the light chain variable region of claim 1. 16. Химерное антитело, которое связывается с CD40 человека, содержащее вариабельный участок легкой цепи и вариабельный участок тяжелой цепи, причем указанный вариабельный участок тяжелой цепи имеет аминокислотную последовательность, по крайней мере, на 90% идентичную последовательности вариабельного участка тяжелой цепи по п. 2.16. A chimeric antibody that binds to human CD40 comprising a light chain variable region and a heavy chain variable region, said variable heavy chain region having an amino acid sequence that is at least 90% identical to the sequence of the variable region of the heavy chain according to claim 2. 17. Способ лечения больного, страдающего от заболевания, опосредованного Т-клетками, предусматривающий введение указанному больному терапевтически эффективной дозы фармацевтической композиции по п. 14.17. A method of treating a patient suffering from a T-cell mediated disease, comprising administering to said patient a therapeutically effective dose of a pharmaceutical composition according to claim 14. 18. Молекула нуклеиновой кислоты по п. 7, имеющая последовательность нуклеотидов SEQ ID NO:6.18. The nucleic acid molecule according to claim 7, having the nucleotide sequence of SEQ ID NO: 6. 19. Молекула нуклеиновой кислоты по п. 8, имеющая последовательность нуклеотидов SEQ ID NO:5.19. The nucleic acid molecule according to claim 8, having the nucleotide sequence of SEQ ID NO: 5. 20. Химерное антитело по п. 6, содержащее легкую цепь с аминокислотной последовательностью SEQ ID NO:4 и тяжелую цепь с аминокислотной последовательностью SEQ ID NO:3.20. The chimeric antibody according to claim 6, containing a light chain with the amino acid sequence of SEQ ID NO: 4 and a heavy chain with the amino acid sequence of SEQ ID NO: 3. 21. Гуманизированное антитело по п. 11, содержащее вариабельный участок легкой цепи с последовательностью SEQ ID NO:8.21. The humanized antibody according to claim 11, containing the variable region of the light chain with the sequence of SEQ ID NO: 8. 22. Гуманизированное антитело по п. 11, содержащее вариабельный участок тяжелой цепи с последовательностью SEQ ID NO:10.22. The humanized antibody according to claim 11, containing the variable region of the heavy chain with the sequence of SEQ ID NO: 10. 23. Гуманизированное антитело по п. 12, содержащее вариабельный участок легкой цепи с последовательностью SEQ ID NO:8.23. The humanized antibody according to claim 12, containing the variable region of the light chain with the sequence of SEQ ID NO: 8. 24. Гуманизированное антитело по п. 12, содержащее вариабельный участок тяжелой цепи с последовательностью SEQ ID NO:10.24. The humanized antibody according to claim 12, containing the variable region of the heavy chain with the sequence of SEQ ID NO: 10. 25. Гуманизированное антитело по п. 11, содержащее вариабельный участок легкой цепи с последовательностью SEQ ID NO:8 и вариабельный участок тяжелой цепи с последовательностью SEQ ID NO:10.25. The humanized antibody of claim 11, comprising the variable region of the light chain with the sequence of SEQ ID NO: 8 and the variable region of the heavy chain with the sequence of SEQ ID NO: 10. 26. Гуманизированное антитело по п. 11, содержащее вариабельный участок легкой цепи с последовательностью SEQ ID NO:12.26. The humanized antibody of claim 11, comprising the variable region of the light chain with the sequence of SEQ ID NO: 12. 27. Гуманизированное антитело по п. 26, содержащее вариабельный участок тяжелой цепи с последовательностью SEQ ID NO:10.27. The humanized antibody of claim 26, comprising the variable region of the heavy chain with the sequence of SEQ ID NO: 10. 28. Гуманизированное антитело по п. 11, содержащее вариабельный участок легкой цепи с последовательностью SEQ ID NO:12 и вариабельный участок тяжелой цепи с последовательностью SEQ ID NO:10.28. The humanized antibody of claim 11, comprising the variable region of the light chain with the sequence of SEQ ID NO: 12 and the variable region of the heavy chain with the sequence of SEQ ID NO: 10. 29. Фармацевтическая композиция, содержащая гуманизированное антитело по п. 25.29. A pharmaceutical composition comprising the humanized antibody of claim 25. 30. Фармацевтическая композиция, содержащая гуманизированное антитело по п.28.30. A pharmaceutical composition comprising the humanized antibody of claim 28.
RU2000124084/13A 1998-02-19 1999-02-10 Chimeric antibody that binds with human cd40 (variants), nucleic acid molecule (variants), expression vector (variants), humanized antibody (variants), pharmaceutical composition for treatment of disease mediated by t-cells (variants), method for treatment of patient with diseases mediated by t-cells (variants) RU2220980C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/026,291 US6051228A (en) 1998-02-19 1998-02-19 Antibodies against human CD40
US09/026,291 1998-02-19

Publications (2)

Publication Number Publication Date
RU2000124084A true RU2000124084A (en) 2003-11-10
RU2220980C2 RU2220980C2 (en) 2004-01-10

Family

ID=21830976

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000124084/13A RU2220980C2 (en) 1998-02-19 1999-02-10 Chimeric antibody that binds with human cd40 (variants), nucleic acid molecule (variants), expression vector (variants), humanized antibody (variants), pharmaceutical composition for treatment of disease mediated by t-cells (variants), method for treatment of patient with diseases mediated by t-cells (variants)

Country Status (31)

Country Link
US (3) US6051228A (en)
EP (1) EP1054692A4 (en)
JP (1) JP2002503495A (en)
KR (1) KR100564376B1 (en)
CN (1) CN1198647C (en)
AR (1) AR018101A1 (en)
AU (1) AU751064B2 (en)
BG (1) BG65010B1 (en)
BR (1) BR9908045A (en)
CA (1) CA2321165A1 (en)
CO (1) CO4830493A1 (en)
CZ (1) CZ20003008A3 (en)
EE (1) EE200000470A (en)
GE (1) GEP20033016B (en)
HU (1) HUP0100763A3 (en)
ID (1) ID25792A (en)
IL (2) IL137294A0 (en)
LT (1) LT4837B (en)
LV (1) LV12561B (en)
MY (1) MY121464A (en)
NO (1) NO20004133L (en)
NZ (1) NZ505696A (en)
PE (1) PE20000268A1 (en)
PL (1) PL197143B1 (en)
RU (1) RU2220980C2 (en)
SK (1) SK12092000A3 (en)
TR (1) TR200002405T2 (en)
TW (1) TWI226334B (en)
UA (1) UA71909C2 (en)
WO (1) WO1999042075A2 (en)
ZA (1) ZA991307B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288251B2 (en) 2001-11-09 2007-10-30 Abgenix, Inc. Antibodies to CD40

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US7153508B2 (en) * 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7175847B1 (en) * 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
DE69731836T2 (en) * 1996-07-23 2005-12-01 Pangenetics B.V. INDUCTION OF T CELL TOLERANCE USING A SOLUBLE MOLECULAR THAT CAN CREATE TWO COSTIMULATION PATHS AT THE SAME TIME
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
WO2000066155A1 (en) 1999-04-30 2000-11-09 La Jolla Institute For Allergy And Immunology Methods for preventing reactivation of latent virus and controlling virus replication
WO2000067796A1 (en) 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US7074403B1 (en) * 1999-06-09 2006-07-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
US8119101B2 (en) * 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
WO2001013945A1 (en) * 1999-08-23 2001-03-01 Biocrystal Ltd. Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
EP1839674A1 (en) * 1999-10-04 2007-10-03 Novartis Vaccines and Diagnostics, Inc. CD40 antagonist for treating psoriasis
WO2001024823A1 (en) * 1999-10-04 2001-04-12 Chiron Corporation Cd40 antagonist for treating psoriasis
US6849425B1 (en) * 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
AU1590201A (en) * 1999-11-09 2001-06-06 Chiron Corporation Compositions and methods for treating autoimmune diseases and transplant rejections
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
GB0006398D0 (en) * 2000-03-16 2000-05-03 Novartis Ag Organic compounds
JP2004505927A (en) * 2000-04-19 2004-02-26 タノックス インコーポレイテッド CD40 antagonist for the treatment of psoriasis and other inflammatory skin conditions
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
CA2422076A1 (en) * 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
DE60239931D1 (en) * 2001-04-02 2011-06-16 Genentech Inc COMBINATION THERAPY
EP2009027B1 (en) * 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
WO2003024480A2 (en) * 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
CA2466931A1 (en) * 2001-11-26 2003-06-05 Chiron Corporation Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
EP2865688A1 (en) * 2002-03-01 2015-04-29 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
AU2003300842A1 (en) * 2002-12-09 2004-06-30 Tolerrx, Inc. Inducing tolerance in primates
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
ATE447412T1 (en) * 2003-11-04 2009-11-15 Novartis Vaccines & Diagnostic ANTAGONIST ANTI-CD40 MONOCLONAL ANTIBODIES AND METHODS OF USE
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
US7674884B2 (en) * 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
US7312320B2 (en) * 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US20110171126A1 (en) * 2010-01-11 2011-07-14 Center For Molecular Medicine And Immunology Enhanced Cytotoxicity of Anti-CD74 and Anti-HLA-DR Antibodies with Interferon-Gamma
CN1980957A (en) 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 Receptor coupling agents and therapeutic uses thereof
WO2006046935A1 (en) * 2004-10-22 2006-05-04 Applied Molecular Evolution, Inc Methods of optimizing antibody variable region binding affinity
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
KR101235484B1 (en) * 2005-04-06 2013-02-22 브리스톨-마이어스 스큅 컴퍼니 Methods for Treating Immune Disorders Associated with Graft Transplantaton with Soluble CTLA4 Mutant Molecules
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
DK1889065T3 (en) * 2005-05-18 2013-09-02 Xoma Technology Ltd METHODS OF DIAGNOSIS AND TREATMENT OF DISEASES WITH AN AUTO-IMMUNE AND / OR INFLAMMATION COMPONENT
US8303955B2 (en) * 2005-05-26 2012-11-06 Seattle Genetics, Inc. Humanized anti-CD40 antibodies and their methods of use
US7668387B2 (en) * 2005-06-20 2010-02-23 Intel Corporation Selective local transient improvement and peaking for video sharpness enhancement
DK1912675T3 (en) * 2005-07-25 2014-03-24 Emergent Product Dev Seattle B-cell reduction using specific and cd37-cd20-specific binding molecules
US20080131914A1 (en) * 2005-09-14 2008-06-05 Ahearn Joseph M Assessing risk of cerebrovascular thrombosis by measuring c4d
US20070202549A1 (en) * 2005-09-14 2007-08-30 University Of Pittsburgh Assessing risk of cerebrovascular thrombosis by measuring C4d on platelets
WO2007033369A2 (en) * 2005-09-14 2007-03-22 University Of Pittsburgh Assessing risk of cerebrovascular thrombosis by measuring c4d on platelets
ES2400660T3 (en) 2005-11-01 2013-04-11 Novartis Ag Uses of anti-CD40 antibodies
MEP39508A (en) 2006-04-21 2011-02-10 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
MX2008013993A (en) * 2006-05-03 2009-05-11 Univ Colorado Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity.
EP1854810A1 (en) * 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
MX2009001226A (en) * 2006-08-04 2009-03-20 Baxter Int Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes.
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
JP5469600B2 (en) 2007-07-16 2014-04-16 ジェネンテック, インコーポレイテッド Anti-CD79b antibody and immunoconjugate and method of use thereof
TW200918089A (en) * 2007-07-16 2009-05-01 Genentech Inc Humanized anti-CD79b antibodies and immunoconjugates and methods of use
SI2657253T1 (en) 2008-01-31 2017-10-30 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
AU2010222929B2 (en) * 2008-07-16 2013-07-25 Baylor Research Institute Antigen presenting cell targeted anti-viral vaccines
DK2406289T3 (en) 2009-03-10 2017-05-01 Baylor Res Inst ANTIGEN PRESENTING CELL TARGETED ANTIVIRUS VACCINES
HUE038788T2 (en) 2010-03-31 2018-11-28 Boehringer Ingelheim Int Anti-CD40 antibodies
HUE060541T2 (en) * 2010-05-14 2023-03-28 Univ Leland Stanford Junior Humanized and chimeric monoclonal antibodies to cd47
AR083847A1 (en) 2010-11-15 2013-03-27 Novartis Ag FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES
PT2683406T (en) 2011-03-11 2019-07-08 Beth Israel Deaconess Medical Ct Inc Anti-cd40 antibodies and uses thereof
AU2012245309C1 (en) 2011-04-21 2016-07-21 Bristol-Myers Squibb Company Antibody polypeptides that antagonize CD40
EP3508500A1 (en) 2011-04-29 2019-07-10 Apexigen, Inc. Anti-cd40 antibodies and methods of use
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
AR088455A1 (en) 2011-10-13 2014-06-11 Bristol Myers Squibb Co ANTIBODIES THAT ANTAGONIZE CD40L
CA2853138A1 (en) 2011-12-05 2013-06-13 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
CN104918957B (en) 2012-10-30 2018-11-16 埃派斯进有限公司 Anti-CD 40 antibodies and its application method
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
HRP20220399T1 (en) 2012-12-13 2022-05-13 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
AU2015204503B2 (en) 2014-01-13 2020-07-09 Baylor Research Institute Novel vaccines against HPV and HPV-related diseases
CN106029098A (en) 2014-02-25 2016-10-12 免疫医疗公司 Humanized RFB4 anti-CD22 antibody
EP3113796A1 (en) 2014-03-07 2017-01-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
MX2017001864A (en) 2014-08-12 2017-08-02 Alligator Bioscience Ab Combination therapies with anti cd40 antibodies.
EP3194442A4 (en) * 2014-09-16 2018-05-23 UBI IP Holdings Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition
PL3262071T3 (en) 2014-09-23 2020-08-10 F. Hoffmann-La Roche Ag Method of using anti-cd79b immunoconjugates
SG11201702598XA (en) 2014-10-29 2017-05-30 Seattle Genetics Inc Dosage and administration of non-fucosylated anti-cd40 antibodies
US9888673B2 (en) 2014-12-10 2018-02-13 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
EP3286224A4 (en) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
HUE048284T2 (en) 2015-05-29 2020-07-28 Abbvie Inc Anti-cd40 antibodies and uses thereof
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
CN116063481A (en) 2015-09-04 2023-05-05 普里玛托普医疗股份有限公司 Humanized anti-CD 40 antibodies and uses thereof
CN109069622A (en) 2015-09-30 2018-12-21 詹森生物科技公司 Specifically bind the antagonistic antibodies and application method of people CD40
CA3011372A1 (en) 2016-02-10 2017-08-17 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
WO2017156349A1 (en) 2016-03-10 2017-09-14 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
WO2017189279A1 (en) 2016-04-27 2017-11-02 Immunomedics, Inc. Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
TWI784957B (en) 2016-06-20 2022-12-01 英商克馬伯有限公司 Immunocytokines
WO2018183041A1 (en) 2017-03-27 2018-10-04 Immunomedics, Inc. Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor
EP3606964A4 (en) 2017-04-03 2020-12-09 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
KR20210033029A (en) 2018-07-20 2021-03-25 유큐(베이징) 바이오파마 코., 엘티디 Anti-CD40 antibodies and uses thereof
US20200190163A1 (en) * 2018-10-26 2020-06-18 Lijun Wu Humanized bcma-car-t cells
KR20210109520A (en) * 2018-12-28 2021-09-06 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 Antibodies and their uses
CN111454363B (en) * 2019-03-04 2021-03-02 北京天广实生物技术股份有限公司 CD40 antibodies and uses thereof
JP2022547850A (en) * 2019-09-03 2022-11-16 バイオ - テラ ソリューションズ、リミテッド Anti-TIGIT immune inhibitor and application
CN113563473A (en) 2020-04-29 2021-10-29 三生国健药业(上海)股份有限公司 Tetravalent bispecific antibody, preparation method and application thereof
CN111763259B (en) * 2020-09-03 2020-12-15 北京百奥赛图基因生物技术有限公司 anti-CD 40 antibodies and uses thereof
CN117500816A (en) 2021-08-26 2024-02-02 映恩生物制药(苏州)有限公司 Steroid and conjugate thereof
WO2023044048A1 (en) * 2021-09-17 2023-03-23 Novartis Ag Methods for prevention of graft rejection in xenotransplantation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU3226593A (en) * 1991-11-26 1993-06-28 Regents Of The University Of California, The Cloning vectors for expressing pcr generated variable regions as complete heavy and/or light chain(s)
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
DK0766745T3 (en) * 1995-04-08 2002-11-25 Lg Chemical Ltd Monoclonal antibody specific for human 4-1BB as well as cell line producing this
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
KR20000034847A (en) * 1998-11-17 2000-06-26 성재갑 Humanized Antibody Specific for Human 4-1BB Molecule and Pharmaceutical Composition Comprising Same

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288251B2 (en) 2001-11-09 2007-10-30 Abgenix, Inc. Antibodies to CD40
US7338660B2 (en) 2001-11-09 2008-03-04 Abgenix, Inc. Methods of treating cancer and enhancing immune responses with antibodies that bind CD40
US7563442B2 (en) 2001-11-09 2009-07-21 Abgenix, Inc. Antibodies to CD40 and methods of treating cancer and enhancing immune responses
US7618633B2 (en) 2001-11-09 2009-11-17 Amgen Fremont Inc. Antibodies that bind CD40 and methods of treating cancer and enhancing immune responses
US7626012B2 (en) 2001-11-09 2009-12-01 Amgen Fremont Inc. Nucleic acid molecules which encode antibodies that bind CD40
US8388971B2 (en) 2001-11-09 2013-03-05 Amgen Fremont Inc. Antibodies that bind CD40 and methods of treating cancer and enhancing immune responses

Similar Documents

Publication Publication Date Title
RU2000124084A (en) Chimeric antibody that binds to human CD40 (variants), nucleic acid molecule (variants), expression vector (variants), humanized antibody (variants), pharmaceutical composition for treating a T-cell mediated disease (variants), method for treating a patient for a disease mediated by T cells (options)
RU2220980C2 (en) Chimeric antibody that binds with human cd40 (variants), nucleic acid molecule (variants), expression vector (variants), humanized antibody (variants), pharmaceutical composition for treatment of disease mediated by t-cells (variants), method for treatment of patient with diseases mediated by t-cells (variants)
RU2207878C2 (en) "humanized" antibodies raised against human gp39, compositions comprising these antibodies and their therapeutic using
RU2421464C2 (en) Human il-13 antibodies and their therapeutic application
KR920002315B1 (en) Polypeptides complementary to peptides or proteins having an amino acid sequence or nucleolide coding sequence at least partially known and methods of design therefor
RU2432364C2 (en) POLYCLONAL Nogo ANTIBODY, PHARMACEUTICAL COMPOSITION AND APPLICATION OF ANTIBODY FOR PREPARING DRUG
NO20074516L (en) Mammalian cytokine-like polypeptide-1
RU2000109255A (en) "HUMANIZED" ANTIBODIES AGAINST HUMAN GP39, COMPOSITIONS CONTAINING THESE ANTIBODIES AND THEIR THERAPEUTIC USES
CA2189015A1 (en) Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases
IL212686A0 (en) Oligodendrocyte binding human monoclonal igm antibodies and compositions and uses thereof
RU94045919A (en) Antibodies, cells, polypeptide, dna, vectors, method of polypeptide preparing, method of antibody preparing, pharmaceutical composition
RU2009149294A (en) ANTIGEN BINDING PROTEINS AIMED AT ORF0657N S.AUREUS
EA200300381A1 (en) NUCLEIC ACIDS AND POLYPEPTIDES OF THE NEW RECEPTOR
RU2002113920A (en) ANTIGENIC PEPTIDES NEISSERIA
RU2006101149A (en) RECOMBINANT ADENO-ASSOCIATED VIRAL VECTOR FOR TREATMENT OF ALZHEIMER'S DISEASE
WO1995021919A3 (en) Protein having tpo activity
RU98120519A (en) AUTOANTIGEN AND STRUCTURAL-RELATED PROTEINS FOR USE IN IMMUNOTHERAPY OF AUTOIMMUNE DISEASES
RU97105374A (en) MODIFIED PROTEINS
JP2009524428A5 (en)
CA2370098A1 (en) Human beta-trcp protein
ATE310828T1 (en) IMPLANT AND VECTOR FOR THE TREATMENT OF ACQUIRED DISEASES
RU2003129163A (en) POLINUCLEOTID, WHICH CAN BE USED TO MODULATE CANCER CELL PROLIFERATION
RU97104072A (en) BODY WEIGHT MODULATORS ACCORDING TO NUCLEIC ACIDS AND PROTEINS, AND ALSO THEIR APPLICATION FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
WO2004110355A3 (en) Compositions and methods including a recombinant human mab that promotes cns remyelination
JP4310498B2 (en) Human IgM antibody that induces apoptosis in HIV-infected cells and therapeutic agent for HIV infection